News & Analysis as of

Canada Opioid

Bennett Jones LLP

Supreme Court Approves Constitutionality of Multi-Crown Class Action

Bennett Jones LLP on

The Supreme Court of Canada (SCC) has endorsed the constitutionality of British Columbia (BC) legislation empowering the province to seek recovery of opioid epidemic healthcare costs in a proposed class action brought on...more

Skadden, Arps, Slate, Meagher & Flom LLP

Trump’s Tariffs on Canada, Mexico and China: Update and Analysis

On February 1, 2025, President Donald Trump signed executive orders imposing tariffs on almost all imports from Canada, Mexico and China. Tariffs on China became effective on February 4, 2025, while Canada and Mexico reached...more

Bennett Jones LLP

Supreme Court of Canada Endorses Comity in Class Proceedings in Response to the Opioid Epidemic

Bennett Jones LLP on

A national class action on behalf of multiple Canadian governments to recover opioid epidemic healthcare costs simplifies the aggregation, prosecution, and determination of claims that span geographic boundaries. That is what...more

Smart & Biggar

Class actions relating to opioid use disorder continue across Canada

Smart & Biggar on

There are multiple ongoing class actions in Canada against pharmaceutical companies related to Opioid Use Disorder (OUD) and its effects. While these proceedings are all currently in their early stages, decisions have...more

Bennett Jones LLP

Ontario Provides Details on Workplace Naloxone Kit Requirements

Bennett Jones LLP on

On December 12, 2022, the Ontario Legislature published Regulation 559/22: Naloxone Kits (Regulation) providing further details on the naloxone kit requirements introduced as part of the Working for Workers Act, 2022, (Bill...more

Littler

Ontario, Canada Publishes Regulation on Naloxone Kit Requirement

Littler on

As discussed, on December 8, 2022, Ontario proclaimed in force amendments to the Occupational Health and Safety Act made in Bill 88, Working for Workers Act, 2022. The amendments, which require certain employers to have...more

Littler

Ontario, Canada: Occupational Health and Safety Act Amendments Requiring Certain Employers to Have Naloxone Kits Proclaimed in...

Littler on

On December 8, 2022, Ontario proclaimed in force amendments to the Occupational Health and Safety Act (OHSA) made in Bill 88, Working for Workers Act, 2022.  The amendments, which require certain employers to have naloxone...more

Smart & Biggar

B.C. Supreme Court declines to strike Province’s class action claims to recover healthcare costs and damages related to opioid...

Smart & Biggar on

In August 2018, the Province of British Columbia (Province) commenced a class action on behalf of itself and other provincial and federal governments against approximately 50 pharmaceutical manufacturers, wholesalers, and...more

Bennett Jones LLP

B.C. Court of Appeal Provides its First Pronouncement on Sequencing Issues

Bennett Jones LLP on

The B.C. Court of Appeal’s decision in British Columbia v The Jean Coutu Group (PJC) Inc., 2021 BCCA 219, is the first time the B.C. Court of Appeal has weighed in on class action sequencing issues. The core issue on appeal...more

FordHarrison

[Webinar] New Jersey Up in Smoke...Medical Marijuana, Drug Testing, and the Workplace - June 4th, 2:00pm ET

FordHarrison on

Statutory changes, medical marijuana, opioids and more are generating much “hand wringing” among officials and managers and human resources professionals. Join FordHarrison New Jersey based attorneys Keya Denner and Mark...more

Smart & Biggar

Rx IP Update - May 2018

Smart & Biggar on

An Update on Vanessa’s Law - This is a special update on the Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law) which was approved on November 6, 2014 (as previously reported), amending the Food and Drugs Act...more

Smart & Biggar

Rx IP Update - July 2017

Smart & Biggar on

Supreme Court of Canada strikes down "promise doctrine", upholds AstraZeneca’s NEXIUM patent as useful - As previously reported, on June 30, 2017, the Supreme Court of Canada granted AstraZeneca’s appeal in the NEXIUM...more

12 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide